The McLean IRB meet on Wednesday to review the MDMA/cancer anxiety study. They have some concerns that we need to address but it seems like they are rather straightforward issues so it’s possible …
The third subject participated in his first experimental session in Dr. Mithoefers’ MAPS-sponsored MDMA/PTSD study, without any adverse side effects. Several additional subjects are also scheduled …
The second experimental session took place today for the second subject. (Due to scheduling complications, the first subject’s second session is scheduled for next week.) The session, which went …
Nature publishes a lengthy article and editorial about MDMA psychotherapy research. The articles, about which Rick Doblin has written a lengthy commentary, are supportive of MAPS’ research efforts. …
The second subject participated in her first experimental session (MDMA or placebo). Each subject will receive two experimental sessions, two to three weeks apart, in additional to about 8 non-drug psychotherapy …
Historic Days! The first experimental session in MAPS’ MDMA/PTSD study took place today. Both the subject and the experimental team guessed that the substance that was administered was MDMA instead …
A DEA-licensed pharmacist, a Randomization Monitor, and Dr. Mithoefer are creating the MDMA and placebo capsules today for use in the MDMA/PTSD study. The process is being filmed by a camera crew from …
IRB approval was extended another six months, to September 15, 2004, or until the first Data Safety Monitoring Board (DSMB) report is available. Approval is conditional upon review of the data on an ongoing …
MDMA arrives! Today the tiny amount of MDMA required for the MDMA/PTSD study (4 grams) arrived, shipped with all the appropriate DEA forms and procedures. Patients are being scheduled for screening to …
Rick Doblin was the guest in a live email chat on the Chronicle for Higher Education website. To read the exchanges, see the transcript. CNN announces that Ecstasy is Approved for Medical Study. Corrections …
The DEA issued Dr. Mithoefer a Schedule 1 license. The first MDMA-assisted psychotherapy research project since MDMA was criminalized in 1985 now has the necessary regulatory approval from the FDA, the …
Dr. Mithoefer received a call from DEA indicating they have not received the official reply from FDA yet in response to their request for a consultation. However, they know that FDA recommended that he …
